Mechanism of Action
OTR-AC shares the complete mechanism of action of BPC-157 — the peptide sequence is unchanged. For a full mechanistic breakdown see the BPC-157 wiki page. Below are the oral-route-specific pharmacological considerations.
Why Oral Dosing Requires More
Peptides face two degradation challenges in the GI tract: (1) acid hydrolysis in the low-pH stomach environment and (2) enzymatic cleavage by intestinal peptidases (pepsin, trypsin, chymotrypsin). BPC-157 is comparatively resistant to acid hydrolysis due to its proline-rich sequence but loses a significant fraction to enzymatic degradation. Oral bioavailability is estimated at 10–25% relative to subcutaneous injection, requiring 2–5 mg oral to approximate the tissue-level effects of 250–500 µg subcutaneous.[1]GI Mucosal Advantage
Oral administration exposes the entire GI mucosal surface to the peptide before absorption, producing direct local anti-inflammatory, angiogenic, and barrier-repair effects that systemic circulation via injection cannot achieve efficiently. This is the core pharmacological argument for oral OTR-AC over injectable BPC-157 for gut-specific indications including leaky gut, IBD, gastric ulcers, and GLP-1-related GI side effects.[2]Enteric Signaling
BPC-157 interacts with the enteric nervous system and vagus nerve. Oral delivery may enhance this gut-brain signaling pathway relative to subcutaneous injection by delivering the peptide directly to the luminal side of the enteric plexus.[3]Research Overview
OTR-AC Specific Research
Limited Direct DataNo peer-reviewed clinical trials have been conducted specifically on oral BPC-157 acetate at the 2–5 mg dosing range used in self-research. The "OTR-AC" nomenclature originates in community usage rather than academic literature. Available data is extrapolated from parent BPC-157 studies and pharmacokinetic modeling of oral peptide bioavailability.[1]
Parent BPC-157 Evidence Base
Extensively StudiedThe parent compound BPC-157 has over 100 published preclinical studies demonstrating efficacy for GI mucosal repair, tendon healing, neurological protection, and anti-inflammatory effects. These findings are considered applicable to OTR-AC at equivalent molar tissue doses. See the BPC-157 wiki page for the complete evidence base.[2]
GLP-1 Stack Rationale
Community DataGrowing self-research community reports describe OTR-AC co-administration with GLP-1 receptor agonists (Tirzepatide, Semaglutide) to counteract GI side effects including nausea, gastroparesis, and mucosal irritation. The mechanistic basis is plausible — BPC-157 accelerates gastric emptying recovery and reduces GI inflammation via pathways distinct from GLP-1 signaling — but controlled data is absent.[3]
Calculate your OTR-AC dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gut repair / leaky gut | 2–3 mg | Once daily | Oral, empty stomach |
| GLP-1 GI side effect mitigation | 2 mg | Once daily (morning, before GLP-1 dose) | Oral |
| IBD / colitis protocol | 3–5 mg | Once or twice daily | Oral |
| Systemic healing (oral alternative) | 5 mg | Once daily | Oral |
Take on an empty stomach (30–60 minutes before food) to maximize GI mucosal contact time and reduce competitive degradation from dietary peptides. Capsule or powder dissolved in a small volume of water (20–30 mL) both work. For GLP-1 stacking, take OTR-AC in the morning and GLP-1 dose as normal.
Doses extrapolated from BPC-157 preclinical data with oral bioavailability correction. Not medical advice.
Peptide Interactions
Safety Profile
OTR-AC inherits the safety profile of BPC-157. No additional risks are introduced by the oral route or acetate salt counterion.
GI tolerability: Oral BPC-157 is well-tolerated in animal models. Community reports indicate rare GI discomfort at doses above 5 mg, resolving with dose reduction. No significant adverse events reported at 2–5 mg daily range.
Acetate counterion: The acetate ion is physiologically produced endogenously (acetyl-CoA metabolism). No additional safety concern at counterion quantities present in typical doses.
Drug interactions: No known pharmacokinetic interactions. BPC-157 does not inhibit CYP450 enzymes in available data.
Populations to avoid: Insufficient data for use during pregnancy, breastfeeding, or active malignancy. Standard preclinical compound caution applies.
References
- [1]Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des. 2018;24(18):1990-2001. PMID:29680568
- [2]Sikiric P, et al. "A novel peptide, BPC 157, abrogates the effects of cuprizone-induced demyelination." J Neuroimmunol. 1999. PMID:10402546
- [3]Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011. PMID:31035095